Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2021-12-13 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Positive UK PIP Decision & PDCO opinion ratification by EMA 2 pages 127.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 December 2021 from Antisense Therapeutics Limited. It reports a positive regulatory decision from the UK MHRA on a Paediatric Investigation Plan (PIP) and ratification of a PDCO opinion by the EMA. The content focuses on regulatory approvals and clinical trial progress for a drug development program. There are no financial statements, earnings data, or detailed financial analysis. The document is an announcement of regulatory and clinical development updates rather than a full report or presentation. It is not a call transcript, annual report, or management report. The document is a regulatory announcement about clinical trial and regulatory progress, fitting best under Regulatory Filings (RNS). The document length (7677 characters) is sufficient for a substantive announcement but does not contain financial data or detailed report content. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-12-13 English
ATL1102 Toxicology Protocol submitted to US FDA 2 pages 102.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 December 2021 from Antisense Therapeutics Limited regarding the submission of a toxicology protocol to the US FDA. It discusses regulatory interactions, clinical trial plans, and potential receipt of a priority review voucher (PRV). The content is focused on regulatory and clinical development updates rather than financial results, management changes, or shareholder voting. The document is relatively short (7,339 characters) and serves as an announcement of a regulatory submission and strategic update rather than a detailed report or transcript. There is no indication of financial statements, earnings data, or detailed management discussion. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-08 English
Update - Proposed issue of securities - ANP 12 pages 47.5KB
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a proposed issue of securities by Antisense Therapeutics Limited. It includes specifics about an entitlement offer, placement, offer price, security types, issue dates, and other related details. The content is consistent with a capital raising or financing activity, including information about the offer, oversubscription, scale back arrangements, and attaching securities. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a brief announcement but a comprehensive update on a financing event. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-11-22 English
Entitlement Offer Closing Date Extended 2 pages 169.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 23 November 2021 regarding the extension of the closing date for a non-renounceable entitlement offer by Antisense Therapeutics Limited. It provides details about the offer, key dates including the Annual General Meeting date, and background information about the company and its products. The content focuses on a capital raising event and the extension of the offer period, which is a financing activity. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive information about the offer itself. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-11-22 English
Notice of Annual General Meeting/Proxy Form 27 pages 647.9KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed information about the meeting date, time, and virtual attendance instructions. It contains the agenda items for the AGM, including consideration of the Annual Financial Report for the year ended 30 June 2021, resolutions for adoption of the Remuneration Report, election of directors, ratification of prior share issues, and increase to the non-executive director fee pool. The document also includes explanatory notes and proxy forms, which are typical components of an AGM notice. There is no actual financial data or report content included, only the notice and related meeting materials. The document length is about 15,000 characters, which is consistent with a detailed AGM notice including explanatory notes and proxy forms. Therefore, this document is best classified as AGM Information (AGM-R).
2021-11-14 English
Change of Director's Interest Notice - CG 3 pages 280.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares acquired and disposed, the nature of the change, and the value/consideration. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or other report types. Therefore, it fits the definition of Director's Dealing (DIRS). The document length is 3828 characters, which is typical for such notices. Hence, the classification is DIRS with high confidence.
2021-11-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.